LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy therapies, announced a $105 million (€90 million) global license and transfer ...

LEO is claiming global commercial rights to Spevigo for GPP but will also collaborate with Boehringer on potential follow-up ...

LEO Pharma acquires global rights to Spevigo for $105M, boosting its dermatology pipeline and expanding access for patients ...

The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.

Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and ...

INGELHEIM, Germany & BALLERUP, Denmark I July 14, 2025 I Boehringer Ingelheim and LEO Pharma today announced an exclusive global license and transfer ...

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.